

Management of Organophosphorus Poisoning

Sangha Ratna Bajracharya,¹ Pratap Narayan Prasad,² Rakesh Ghimire¹

¹Department of Clinical Pharmacology, ²Department of Emergency and General Practice, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal.

ABSTRACT

Organophosphorus (OP) compounds are widely used for agriculture, domestic pest-control and chemical warfare. Pesticide self-poisoning accounts for one-sixth to one-eighth of the world's suicides and a third of suicide deaths in rural Asia each year. OP pesticides inhibit cholinesterase enzymes leading to overstimulation of cholinergic receptors. Clinical features depend on the types of receptors stimulated at various sites of the body. The diagnosis of OP poisoning is made on the basis of history of poisoning, smell of pesticides, the characteristic clinical signs and reduced cholinesterase activity. Measurement of plasma cholinesterase is useful for diagnosis of OP poisoning although it may not directly correlate with severity of the poisoning. Atropine remains the main stay of treatment of OP poisoning with clear evidence of benefit if administered effectively. Atropine therapy should be monitored to maintain systolic blood pressure > 80 mmHg, pulse > 80 beats/min and clear chest on auscultation. Oximes reactivate cholinesterase enzymes and help to overcome even the nicotinic effects of OP poisoning. However, evidence for its effectiveness after self-poisoning is weak. Although several newer adjuvant therapies are tried to achieve better outcome, their potential benefits are not yet established.

Keywords: Cholinesterase management; organophosphorus poisoning.

INTRODUCTION

Organophosphorus (OP) compounds are widely used for agriculture, domestic pest-control and chemical warfare.¹ An estimated 25 million farmers from developing countries suffer from acute pesticide poisoning annually.² Pesticide self-poisoning accounts for one-six to one-eighth of the world's suicides and about 60% of the deaths from pesticide self-poisoning in rural Asia each year.³⁻⁵

Hospital based studies in Nepal revealed OP compounds as the most common poisoning agent comprising 52% of total cases.⁶ Use of OP pesticides is widespread in Nepal, mainly in agricultural region. The OP compounds hold a major share of in-patient deaths among poisoning cases admitted in Nepalese hospitals⁷⁻⁹ and methyl parathion is the most commonly consumed OP compound.^{10,11}

The treatment outcome depends upon efficient intensive care and use of antidotes.¹² Atropine remains the main

stay of treatment with weak evidence of benefit by oximes. Availability of standard treatment protocol in the hospital is a key to reduce the case fatality from OP poisoning.^{13,14}

CLINICAL FEATURES

Organophosphorous (OP) pesticides inhibit cholinesterase enzymes irreversibly,¹⁵ especially acetylcholinesterase (AChE) in synapses and on red-cell membranes, and butyrylcholinesterase (BuChE) in plasma. This leads to accumulation of acetylcholine and subsequent stimulation of cholinergic receptors at the neuromuscular junctions and in the autonomic and central nervous systems. Clinical features of OP pesticide poisonings depend on the types of cholinergic receptors stimulated at various sites in the body (Table 1).

Intermediate syndrome (IMS) is a distinct clinical entity

Correspondence: Dr Sangha Ratna Bajracharya, Department of Clinical Pharmacology, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal. E-mail: sanghab@hotmail.com, Phone: +977 9851007969.

Table 1. Clinical features of organophosphorus poisonings¹⁶⁻¹⁸

Muscarinic receptors in parasympathetic system	Nicotinic receptors in sympathetic system	Nicotinic and Muscarinic receptors in CNS	Nicotinic receptors at neuromuscular junction
<ul style="list-style-type: none"> • Bronchospasm • Bronchorrhoea • Miosis • Lacrimation • Urination • Diarrhoea • Hypotension • Bradycardia • Vomiting • Salivation 	<ul style="list-style-type: none"> • Tachycardia • Mydriasis • Hypertension • Sweating 	<ul style="list-style-type: none"> • Confusion • Agitation • Coma • Respiratory failure 	<ul style="list-style-type: none"> • Muscle weakness • Paralysis • Fasciculation

occurring 24-96 h after exposure in 10-40% OP poisoning. This syndrome is characterized by neurological findings including weakness of neck flexion, proximal muscle and muscle of respiration, decreased deep tendon reflexes and cranial nerve abnormalities.¹⁹ The exact mechanism of IMS is not known. Varying susceptibilities of various cholinergic receptors, prolonged AChE inhibition, inadequate oxime therapy, down regulation or desensitization of postsynaptic acetylcholine release, muscle necrosis and oxidative stress-related myopathy.²⁰

DIAGNOSIS

The diagnosis of OP poisoning is made on the basis of clinical suspicion, the characteristic clinical signs (Table 1) and smell of pesticides or solvents. It should ideally be confirmed with an assay to measure BuChE activity in plasma (or AChE in whole blood).²¹ Red cell AChE assays measure AChE expressed on the surface of red cells. It is a good marker of such inhibition in synapses and of poisoning severity. This enzyme is measured in whole blood in which BuChE activity has been blocked by an inhibitor. AChE is present at very low levels in human plasma and serum.²² Moreover, the regeneration of AChE is slower than that of BuChE and the rate of spontaneous neuronal anticholinesterase recovery is unclear. Hence, BuChE assays can be relied upon to confirm exposure to an organophosphorus or carbamate pesticide. However, inhibition of BuChE does not give information about clinical severity of the poisoning. Many OP pesticides are

more potent inhibitors of BuChE than they are of AChE; BuChE inhibition might occur to a greater extent than AChE inhibition.²³

In addition, monitoring of BuChE does have a prognostic value. BuChE is produced by liver, and blood concentrations recover by about 7% of normal each day once the OP compound has been eliminated.²⁴ Daily BuChE assays can be used to monitor when enzyme activity starts to rise again, since this recovery suggests that the OP has been eliminated. It would also facilitate the decision to stop the treatment with oximes rationally. Control of temperature and pH are important for cholinesterase assays. The BuChE activity increases by 4% per 1 °C increase in temperature.²⁵

TREATMENT

Initial resuscitation to maintain airway, breathing and circulation, followed by administration of atropine and oxygen are considered to be the mainstays of treatment. An AChE reactivator (an oxime that reactivate AChE by removal of phosphate group) is also used despite their effectiveness being much debated.²⁶⁻²⁸

Resuscitation and stabilization of the patient should be accorded the first priority. Gastric decontamination should be considered only after this and for the cases that have taken large quantity of pesticides presenting

Chart 1. Guidelines for Treatment of Acute Organophosphorus Poisoning.^{30,31}

- Airway; Position: Left Lateral, head down
- Breathing: start high flow oxygen +/- intubation
- Circulation: establish intravenous access with 2 cannula; start infusion of 0.9% Normal Saline (NS) (end points- systolic BP >80 mmHg, Urine Output >0.5 mL/kg/hr)
- Disability: Level of Consciousness (Glasgow Coma Scale), Random Blood Glucose
- Examine: Chest sounds, Blood Pressure (BP), Heart rate (HR), Sweat, pupil size

• Suspected or Confirmed Organophosphorous poisoning

↓

• Give first dose of atropine by IV bolus (3-5 ampoules according to severity)

• Start Pralidoxime 2g IV Over 20-30 mins via 2nd cannula

• Risk Assessment: Agent, Amount, Duration of poisoning, Clinical features, Patient Factors

- ↓
- Patient is agitated: Give diazepam 10mg slow intravenous push (30-40mg/day); Avoid physical restraint, check for hyperthermia
 - Seizure disorder: Give diazepam (10 mg i.v. bolus and 20mg i.v if seizure continue); Use propofol, midazolam if not controlled. **AVOID** haloperidol, atracurium, phenytoin

• After 5 mins, check: Breath sounds, SBP, HR, sweating, pupil size
 Targets: **Clear Chest on auscultation, SBP >80 mmHg, HR >80/min, +/- dry skin**

↓

- No improvement: Double the previous dose of atropine
- Improvement seen: Use similar or smaller doses
- Targets achieved: Start an infusion of atropine at the dose of 10-20% of total required dose every hour.

↑

↑

- ↓
- Continue infusion of atropine and pralidoxime; consider decontamination
 - Monitor HR, SBP, Respiratory functions every 15 mins
 - Observe carefully for intermediate syndrome, recurrent cholinergic symptoms or atropine toxicity

Pralidoxime infusion at the rate of 8mg /kg/hr in 0.9% NS until clinical improvement

Box1. Monitoring treatment with atropine.^{30,31}

Insufficient atropine:

- Cholinergic features will re-emerge
- Atropinise the patient again with optimal atropine dose

During Atropinization:

- Tachycardia: could be due to nicotinic effects of poison, hypoxia, hypovolemia, alcohol withdrawal, or atropine itself; rapid administration of oximes. Continue doubling of dose
- Focal areas of crepitation: could be due to aspiration, atropinisation should not be continued for focal areas of crepitation
- Target (SBP, HR and clear chest) achieved, but pupils constricted: stop atropinisation
- Clear Chest, end points for SBP and HR not achieved (near end point achieved): Clinical judgement required, more atropine probably not required; consider using vasopressors
- Pupil very much dilated: Consider Atropine toxicity

Over atropinisation (Atropine Toxicity):

- Includes agitation, confusion, pyrexia, absent peristalsis, urinary retention, tachycardia
- Stop atropine, wait for 30-60 minutes (till symptoms subside) then continue atropine at 70-80% of previous infusion rate
- Control pyrexia with active cooling (fan, cold water sponging) to avoid hyperthermia induced cardiac arrest

Tapering Atropine:

- It is done on the basis of clinical response.
- Taper by 20% of the current dose at each stage

Intermediate Syndrome:

- Assess flexor neck strength regularly in conscious patients by asking them to lift their head off the bed and hold it in that position while pressure is applied to their forehead. Any sign of weakness is a sign that the patient is at risk of developing peripheral respiratory failure.
- Use of accessory muscles of respiration, nasal flaring, tachypnoea, sweating, cranial nerve palsies and proximal muscle weakness in the limbs with retained distal muscle strength.
- Tidal volume should be checked every 4 hr in such patients. Values less than 5 mL/kg indicate a need for intubation and ventilation

Recurrent Cholinergic crisis:

- Due to release of fat soluble OP pesticides from fat stores, may occur for several days to weeks after ingestion of some OP compounds such as fenthion
- Requires retreatment with atropine and oximes.

within 1-2 hours of ingestion.²⁹ Patients must be carefully observed after stabilization for changes in

atropine needs, worsening respiratory function due to intermediate syndrome and recurrent cholinergic features occurring with fat soluble OP compounds. The current guidelines for treatment of acute OP poisoning are given in the Chart1 and Box1.

ATROPINE

Atropine remains the mainstay of therapy for the management of acute OP poisoning. It acts competitively at the peripheral and central muscarinic receptors and antagonizes the parasympathetic effects of excess acetylcholine at these sites. Sufficient atropine to stabilize the person should be given rapidly through continuous intravenous infusion.

DOSAGE AND ADMINISTRATION

The optimum dose of atropine has not been determined.³² It varies among poisoned people because of variation in the dose and particular OP compound taken and possibly because of co-administration of an oxime (oximes have been proposed to have anticholinergic action at high doses).³³ It's worth considering that being too gentle by using dose of atropine less than 0.6 mg may paradoxically worsen the condition by producing bradycardia due to activation of M₁ autoreceptors which are more sensitive to acetylcholine than M₂ receptors.³⁴

Treatment is given according to the above mentioned guidelines with doubling doses in every 5 minutes with the aim to attain target end-points for atropine therapy by evaluating the improvement in cardiovascular function (systolic blood pressure >80 mmHg, pulse

rate > 80 bpm) and respiratory function (no bronchorrhoea and bronchospasm). The regimen will allow for as much as 70 mg of atropine to be given in stages to a patient in less than 30 min, resulting in rapid stabilization and low risk of atropine toxicity. Once the patient achieves most of the target end-points for atropine therapy i.e. 'fully atropinised', an intravenous infusion is set up to maintain the therapeutic effects of atropine. There are different approaches of atropine infusion, the guidelines suggest an infusion giving every hour about 20% of the total dose needed to initially stabilize the patient and to continue this for first 48 hours before gradually tapering over hours and days.

The main adverse effects of too high an atropine dose are delirium, agitation, hyperthermia, absent bowel sounds and urinary retention.³⁵ If this happens, stop the infusion and wait for 30-60 min for these features to settle before starting again at 70-80% of previous infusion rate.

OXIMES

Oximes (such as pralidoxime, obidoxime, and HI-6) reactivate AChE inhibited by OP poisoning. Reactivation is limited by ageing of the AChE and high concentrations of pesticides. Ageing of AChE takes longer with diethyl OP compounds than with dimethyl OP compounds. In theory, oximes may be effective if started within about 120 hours for diethyl OP poisoning and 12 hours for dimethyl OP poisoning. Treatment may be beneficial if continued for as long as the person is symptomatic because it may take several days for the pesticide concentration to drop below the point at which the rate of reactivation surpasses reinhibition.³⁶

There is currently mixed evidence regarding the clinical effectiveness of oximes and some OP pesticides do not respond well to oximes. However, until the evidence base for oximes becomes clearer, it is difficult to contradict the World Health Organization (WHO) guidelines to give high doses of oxime (pralidoxime chloride 30 mg/kg bolus followed by 8-10 mg/kg/hour for the first two days) to all people with OP poisoning, especially in patients with nicotinic effects.³⁷ Adverse effects of oximes include hypertension, cardiac dysrhythmias (including cardiac arrest after rapid administration), headache, blurred vision, dizziness, and epigastric discomfort. Such adverse effects with pralidoxime have been reported only with either rapid administration or doses > 30 mg/kg bolus. It may be difficult to distinguish these adverse effects from the effects of organophosphorus.³⁸ The infusion can be tapered after 2 days and restarted if there is clinical deterioration with withdrawal of

oximes. However, according to a recent study, doses of PAM guided by the patient's severity instead of strictly following WHO guidelines improve the outcomes of OP poisoning patients.³⁹

BENZODIAZEPINES

Benzodiazepines are the first-line drugs for emergency control of seizures and agitation.⁴⁰ They bind to gamma-aminobutyric acid (GABA)-A receptors, increasing channel opening frequency at the receptor, with subsequent increase in chloride conductance and neuronal hyperpolarization, leading to enhanced inhibitory neurotransmission and antiepileptic action.⁴¹ Routine use of benzodiazepine was supportive in animal model with OP poisoning but conclusive studies in human are lacking.⁴² Patients poisoned with OP pesticides frequently become agitated. The cause is complex, with contributions from the pesticide itself, anxiety, atropine toxicity, hypoxia, alcohol ingested with the poison, and medical complications. Diazepam, lorazepam and midazolam are preferred benzodiazepines to treat seizure or agitation due to OP poisoning or due to drugs used for its treatment.⁴³ Diazepam at the dose of 10 mg given by slow IV push reduces agitation and can be repeated as necessary in an adult up to 30-40 mg per 24 hours.³¹

GASTROINTESTINAL DECONTAMINATION

Gastric lavage is often the first intervention done to poisoned patients at hospitals although no evidence shows any form of gastric decontamination to significantly benefit patients poisoned with OP pesticides (or other poisons).⁴⁴ Gastric lavage may delay administration of activated charcoal and specific treatment for OP poisoning. Gastric decontamination should only be done after the patient has been stabilized and treated with oxygen, atropine, and an oxime.⁴⁵ In patients who have taken a large amount of pesticide and are seen within 1 to 2 hours, consensus is that a single dose of activated charcoal after gastric lavage (using an NG tube and careful administration of small volumes of water) may offer benefit. It should be done in people who consent to this treatment or are unconscious and have had their airway protected.

NEWER THERAPIES

Various forms of therapeutic interventions including newer drugs, fresh frozen plasma and paraoxonases have been tried for management of OP poisoning with the hope of better outcome but results are still inconclusive due to the lack of sufficient data and randomized control trials.⁴⁶ Due to ethical ground, these therapies should not

be independently evaluated against the placebo so they had been evaluated as adjuvant to standard therapy.

MAGNESIUM SULPHATE

Magnesium sulphate is an inhibitor of acetylcholine release in the central nervous system and at peripheral sympathetic and parasympathetic synapses.⁴⁷ The administration of magnesium to animals poisoned with OP pesticides improves outcome, possibly owing to a favourable effects on neuromuscular junction block or increased hydrolysis of some pesticides.⁴⁸ The use of magnesium in acute OP poisoning in humans has been reported in three small studies. In the first study, intravenous administration of magnesium sulphate produced some improvement in neuromuscular function.⁴⁹ The second and third studies reported that magnesium decreased mortality compared with usual care.⁵⁰

CLONIDINE

It is an α_2 adrenergic receptor agonist that reduces acetylcholine synthesis and release from pre-synaptic nerve terminals. It showed beneficial effect in animals when combined with atropine, but effects in human beings are unknown.⁵¹

SODIUM BICARBONATE

Studies in animals revealed that increasing blood pH in non-acidotic mice reduced mortality from OP poisoning.⁵² Although human studies also claimed to have good results with sodium bicarbonate, those studies are not randomized control studies and there is insufficient evidence for generalizing the observation.^{53,54}

In addition, there have been studies with possible benefit following administration of fresh frozen plasma (FFP)⁵⁵, an OP hydrolase like paraoxonase that cleaves OP compounds⁵⁶, and antioxidants to prevent neuronal damage due to oxidative stress in acute OP poisoning.⁵⁷

CONCLUSIONS

OP pesticide poisoning has been assumed major global health challenges and it is the most common poisoning associated with morbidity and mortality. Measurement of plasma cholinesterase is useful to retrospectively diagnose the poisoning although it may not directly correlate with the severity of the poison. Hence, result of plasma cholinesterase should not be awaited to initiate therapy of suspected OP poisoning. Atropine remains the main stay of treatment of OP poisoning. Systolic blood pressure, pulse rate and chest auscultation are vital for

monitoring the atropine therapy. Mixed evidence exists about benefit of oximes, with them being ineffective after ageing has occurred. Several newer adjuvant therapies with potential benefit have emerged. Further evidence has to be backed up by newer researches for establishing their role to bring about better outcome in OP poisoning.

ACKNOWLEDGEMENTS

A special note of thanks to Dr. Michael Eddleston, Professor of Clinical Toxicology and Lister Research Prize Fellow at University of Edinburgh for his expert guidance.

REFERENCES

1. Khajuria V, Shah S, Tandon VR, Gillani Z, Gupta R, Sharma A, Gupta S. Organophosphorus poisoning in a tertiary hospital of north India-a preliminary report. *Bulletin of Pharmaceutical and Medical Sciences (BOPAMS)*. 2013;1(1).
2. Kofod DH, Jors E, Varma A, Bhatta S, Thomsen JF. The use of self-reported symptoms as a proxy for acute organophosphate poisoning after exposure to chlorpyrifos 50% plus cypermethrin 5% among Nepali farmers: a randomized, double-blind, placebo-controlled, crossover study. *Environ Health*. 2016 Dec 13; 15(1):122.
3. Jeyaratnam J. Acute pesticide poisoning: a major global health problem. *World Health Stat Q*. 1990; 43(3):139-44.
4. Van der Hoek W, Konradsen F, Athukorala K, Wanigadewa T. Pesticide poisoning: a major health problem in Sri Lanka. *Social science & medicine* 1998;46(4-5):495-504.
5. World Health Organization. *World Health Report 2002: Reducing risks, promoting healthy life*. Geneva: World Health Organization; 2002.
6. Gupta SK, Joshi MP. Pesticide poisoning cases attending five major hospitals of Nepal. *J Nep Med Assoc* 2002; 41:447-56.
7. Pathak UN, Chhetri PK, Dhungel S, Chokhani R, Devkota KC, Shrestha BO et al. Retrospective study of poisoning cases admitted in nepal medical college teaching hospital. *Nep Med Col J* 2001; 3:101-5.
8. Rauniyar GP, Das BP, Naga Rani MA, Gupta MP, Karki BMS. Retrospective analysis of profile of acute poisoning cases in a tertiary care hospital in eastern Nepal: a four-year database from 1994 to 1997. *J Nep Med Assoc* 1999;

- 38:23-8.
9. Prasad PN, Karki P. Poisoning cases at TUTH emergency: a one-year review. *J Inst Med* 1997; 19:18-24.
 10. Kafle KK, Gyawali KK. Organophosphorus: commonest poisoning agent. *J Inst Med* 1992; 14:228-33.
 11. Paudyal BP. Poisoning: pattern and profile of admitted cases in a hospital in central Nepal. *J Nep Med Assoc* 2005; 44:92-6
 12. Eddleston M, Karalliedde L, Buckley N et al. Pesticide poisoning in the developing world- a minimum pesticides list. *Lancet* 2002; 360:1163-7.
 13. Eddleston M, Phillips MR. Self-poisoning with pesticides. *BMJ* 2004; 328:42-4.
 14. Buckley NA, Karalliedde L, Dawson A, Senanayake N, Eddleston M. Where is the evidence for the management of pesticide poisoning? Is clinical toxicology fiddling while the developing world burns? *J ToxicolClinToxicol* 2004; 42:113-6.
 15. Giacobini E. Cholinesterase inhibitors: from the calabar bean to alzheimer's therapy. In: Giacobini E, editor. *Cholinesterases and cholinesterase inhibitors*. London: Martin Dunitz; 2000. p. 181-227.
 16. Erdman AR. Insecticides. In: Dart RC, Caravati EM, McGuigan MA, editors. *Medical toxicology*, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1475-96.
 17. Clark RF. Insecticides: organic phosphorus compounds and carbamates. In: Goldfrank's toxicological emergencies. 7th ed. New York: McGraw-Hill Professional; 2002. p. 1346-60.
 18. Aaron CK. Organophosphates and carbamates. In: Ford MD, Delaney KA, Ling L J, Erickson T. *Clinical toxicology*. Philadelphia: WB Saunders Company; 2001. p. 819-28.
 19. Karalliedde L, Baker D, Marrs TC. Organophosphate-Induced Intermediate Syndrome. *Toxicological reviews*. 2006 Mar 1;25(1):1-4
 20. Narang U, Narang P, Gupta O. Organophosphorus poisoning: A social calamity. *Journal of Mahatma Gandhi Institute of Medical Sciences*. 2015 Jan 1;20(1):46.
 21. Lotti M. Clinical toxicology of anticholinesterase agents in humans. In: Krieger R, editor. *Handbook of pesticide toxicology*. 2nd ed. San Diego: Academic Press; 2001. vol 2 p. 1043-85.
 22. Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. *BiochemPharmacol*. 2005; 70:1673-84.
 23. Eddleston M, Eyer P, Worek F, Mohamed F, Senarathna L, von Meyer L et al. Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study. *The Lancet* 2005 Oct 28; 366(9495):1452-9.
 24. Mason HJ. The recovery of plasma cholinesterase and erythrocyte acetylcholinesterase activity in workers after over-exposure to dichlorvos. *Occup Med* 2000; 50:343-7.
 25. Reiner E, Buntic A, Trdak M, Simeon V. Effect of temperature on the activity of human blood cholinesterases. *Arch Toxicol* 1974; 32:347-50.
 26. de Silva HJ, Wijewickrema R, Senanayake N. Does pralidoxime affect outcome of management in acute organophosphate poisoning? *Lancet* 1992; 339:1136-8.
 27. Singh S, Batra YK, Singh SM, Wig N, Sharma BK. Is atropine alone sufficient in acute severe organophosphate poisoning? Experience of a north west Indian hospital. *Int J ClinPharmacolTher* 1995; 33:628-30.
 28. Peter JV, Cherian AM. Organic insecticides. *AnaesthIntens Care* 2000; 28:11-21.
 29. American Academy of Clinical Toxicology, European Association of Poison Centres and Clinical Toxicologists. Position statement: Gastric lavage. *J ToxicolClinToxicol* 1997; 35:711-9.
 30. Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. *Lancet* 2008; 371(9612):597-607.
 31. Eddleston M, Dawson A, Karalliedde L, Dissanayake W, Hittarage A, Azher S et al. Early management after self-poisoning with anorganophosphorus or carbamate pesticide: a treatment protocol for junior doctors. *Critical Care*. 2004; 8:391-7.
 32. Eddleston M, Buckley N, Checketts H, Senarathna L, Mohamed F, Sheriff MR et al. Speed of initial atropinisation in significant organophosphorus pesticide poisoning – a systematic comparison of recommended regimens. *J ToxicolClinToxicol* 2004; 42:865-875.
 33. Johnson MK, Jacobsen D, Meredith TJ, Eyer P, Heath AJ, Ligtenstein DA et al. Evaluation of antidotes for poisoning by organophosphorus pesticides. *Emerg Med* 2000; 12:22-37.
 34. Wellstien A, Pitschner HF. Complex dose response curve of atropine in man explained by different functions of

- M1 and M2 cholinceptors. *NaunynSchmiedebergs Arch Pharmacol* 1998; 338:19-27.
35. Heath AJW, Meredith T. Atropine in the management of anticholinesterase poisoning. In: Ballantyne B, Marrs T, editors. *Clinical and experimental toxicology of organophosphates and carbamates*. Oxford: Butterworth Heinemann; 1992. p. 543–54.
 36. Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. *Toxicol Rev* 2003;22:165–190.
 37. International Programme on Chemical Safety. *Poisons Information Monograph G001. Organophosphorus pesticides*. Geneva: World Health Organization [Online]. 1989; updated 1999. [Cited 2016 July 8]. Available from: <http://www.inchem.org/documents/pims/chemical/pimg001.htm>
 38. Bismuth C, Inns RH, Marrs TC. Efficacy, toxicity and clinical uses of oximes in anticholinesterase poisoning. In: Ballantyne B, Marrs TC, editors. *Clinical and experimental toxicology of organophosphates and carbamates*. Oxford: Butterworth Heinemann; 1992. p. 555–77.
 39. Lin CC, Hung DZ, Chen HY. The effectiveness of patient-tailored treatment for acute organophosphate poisoning. *Biomed J*. 2016; 39(6):391-399.
 40. Trinka E. Benzodiazepines used primarily for emergency treatment (diazepam, lorazepam, and midazolam) In: Shorvon SD, Perucca E, Engel J Jr, editors. *Treatment of epilepsies*. 3rd ed. Oxford: Blackwell Publishing; 2009. p. 470–484.
 41. Trinka E, Hofler J, Leitinger M, Brigo F. Pharmacotherapy for status epilepticus. *Drugs* 2015; 75:1499–1521.
 42. Wadia RS, Sadagopan C, Amin RB, Sardesai HV. Neurological manifestations of organophosphate insecticide poisoning. *J NeurolNeurosurg Psych* 1974; 37:841-7.
 43. Senanayake N, Karalliedde L. Neurotoxic effects of organophosphate insecticides: an intermediate syndrome. *N Engl J Med* 1987; 316:761-3.
 44. Eddleston M, Singh S, Buckley N. Organophosphorus poisoning (acute). *ClinEvid* 2005;13:1744-55
 45. Eddleston M, Haggalla S, Reginald K, Sudarshan K, Senthilkumaran M, Karalliedde L et al. The hazards of gastric lavage for intentional self-poisoning in a resource poor location. *ClinToxicol* 2007; 45:136–43.
 46. Blain PG. Organophosphorus poisoning (acute). *BMJ ClinEvid* 2011; 05:2102.
 47. Feldman S, Karalliedde L. Drug interactions with neuromuscular blockers. *Drug Saf* 1996; 15:261-73.
 48. Petroianu G, Toomes LM, Petroianu A, Bergler W, Rufer R. Control of blood pressure, heart rate and haematocrit during high-dose intravenous paraoxon exposure in mini pigs. *J ApplToxicol* 1998; 18:293–8.
 49. Singh G, Avasthi G, Khurana D, Whig J, Mahajan R. Neurophysiological monitoring of pharmacological manipulation in acute organophosphate (OP) poisoning. The effects of pralidoxime, magnesium sulphate and pancuronium. *Electro encephalogrClinNeurophysiol* 1998; 107:140–8.
 50. Pajoumand A, Shadnia S, Rezaie A, Abdi M, Abdollahi M. Benefits of magnesium sulfate in the management of acute human poisoning by organophosphorus insecticides. *Hum ExpToxicol* 2004; 23:565–69.
 51. Liu WF. A symptomatological assessment of organophosphate induced lethality in mice: comparison of atropine and clonidine protection. *Toxicol Lett* 1991; 56:19-32.
 52. Cordoba D, David S, Angulo D, Ramos I. Organophosphate poisoning: modifications in acid base equilibrium and use of sodium bicarbonate as an aid in treatment of toxicity in dogs. *Vet Hum Toxicol* 1983; 25:1-3.
 53. Wong A, Sandron CA, Magalhaes AS, Rocha LC. Comparative efficacy of pralidoxime Vs sodium bicarbonate in rats and humans severely poisoned with OP pesticides. *J ToxicolClinToxicol* 2000; 38:554-5.
 54. Balali-Mood M, Ayati MH, Ali-Akbarian H. Effects of high doses of sodium bicarbonate in acute organophosphate pesticide poisoning. *ClinToxicol* 2005; 43:571-4.
 55. Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized clinical trials. *Br J Haematol* 2004; 126:139-52.
 56. Sogorb MA, Vilanova E, Carrera V. Future applications of phosphotriesterases in the prophylaxis and treatment of organophosphorus insecticide and nerve agent poisonings. *Toxicol Lett* 2004; 151:219-33.
 57. Ranjbar A, Solhi H, Masayekhi HJ, Susanabdi A, Rezaie A, Abdollahi M. Oxidative stress in acute human poisoning with organophosphorus insecticides: a case control study. *Environ ToxicolPharmacol* 2005; 20:88-91.